Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Inventor:
Zhu; Zhaoning
Address:
Plainsboro, NJ
No. of patents:
26
Patents:












Patent Number Title Of Patent Date Issued
8580956 Gamma secretase modulators November 12, 2013
In its many embodiments, the present invention provides a novel class of heterocyclic compounds as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations c
8242112 Heterocyclic aspartyl protease inhibitors August 14, 2012
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, --C(.dbd.S)--, --S(O)--, --S(O).sub.2--, --C(.dbd.O)--, --O--, --C(R.sup.6)(R.sup.7)--, --N(R.sup.5)-- or --C(.dbd.N(R.s
8202854 Heterocyclic aspartyl protease inhibitors June 19, 2012
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein Ar, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as defined in the specification; and pharmaceutical compositions comprising the
8183252 Heterocyclic aspartyl protease inhibitors May 22, 2012
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, --C(.dbd.S)--, --S(O)--, --S(O).sub.2--, --C(.dbd.O)--, --O--, --C(R.sup.6)(R.sup.7)--, --N(R.sup.5)-- or --C(.dbd.N(R.s
8178513 Heterocyclic aspartyl protease inhibitors May 15, 2012
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W, U, X, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are as defined herein, and pharmaceutical compositions comprising the compounds of form
8168641 Aspartyl protease inhibitors May 1, 2012
Disclosed are compounds of formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, U, W, X, R.sup.1, R.sup.2, R.sup.6, R.sup.7, R.sup.30 and R.sup.31 are as described above in the specification. Also disclosed is the method of inh
8110682 Preparation and use of compounds as aspartyl protease inhibitors February 7, 2012
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein A is a bond, --C(O)--, or --C(R.sup.3')(R.sup.4')--; X is --N(R.sup.1)-- or --C(R.sup.6)(R.sup.7)--; Y is --S(O).sub.2--, --C(.dbd.O)
8093254 Aspartyl protease inhibitors January 10, 2012
Disclosed are compounds of formula I (Chemical formula should be inserted here as it appears on abstract in paper form) Formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.14, V, W, X, Y, Z,
8012960 Heterocyclic aspartyl protease inhibitors September 6, 2011
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein Ar, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as defined in the specification; and pharmaceutical compositions comprising the
7973067 Heterocyclic aspartyl protease inhibitors July 5, 2011
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, --C(.dbd.S)--, --S(O)--, --S(O).sub.2--, --C(.dbd.O)--, --O--, --C(R.sup.6)(R.sup.7)--, --N(R.sup.5)-- or --C(.dbd.N(R.s
7879997 Compounds for the treatment of inflammatory disorders February 1, 2011
This invention relates to compounds of the Formula (I): ##STR00001## or a pharmaceutically acceptable salt, solvate or isomer thereof, wherein n, M, V, T, W, X, U, R.sup.1 and R.sup.2 are as disclosed in the present specification, and which compounds are useful for the treatment of
7868000 Aspartyl protease inhibitors January 11, 2011
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein j, k, U, W, R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.6, R.sup.7 and R.sup.7a are as described above in the specification.Also disclosed
7812013 Macrocyclic heterocyclic aspartyl protease inhibitors October 12, 2010
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt, solvate or ester thereof, wherein U, W, X, L, Y, M, Z, c, d, e, f, g, h, s, t, R.sup.1, R.sup.2, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12, R.sup.13,
7763609 Heterocyclic aspartyl protease inhibitors July 27, 2010
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, --C(.dbd.S)--, --S(O)--, --S(O).sub.2--, --C(.dbd.O)--, --O--, --C(R.sup.6)(R.sup.7)--, --N(R.sup.5)-- or --C(.dbd.N(R.sup.5)
7763606 Heterocyclic aspartyl protease inhibitors July 27, 2010
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein Ar, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as defined in the specification; and pharmaceutical compositions comprising the compo
7759354 Bicyclic guanidine derivatives as asparyl protease inhibitors, compositions, and uses thereof July 20, 2010
The present application provides compounds of the Formula: ##STR00001## and stereoisomers, tautomers, or pharmaceutically acceptable salts and solvates thereof, wherein U, W, R, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 in each formula (when present) are as defined in the specification, and
7759353 Substituted spiro iminopyrimidinones as aspartyl protease inhibitors, compositions, and methods July 20, 2010
Disclosed are certain substituted spiro iminopyrimidinones and other compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein U, W, A, R, R.sup.1, R.sup.2, R.sup.6a and R.sup.7, are as defined in the specifi
7700603 Heterocyclic aspartyl protease inhibitors April 20, 2010
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, --C(.dbd.S)--, --S(O)--, --S(O).sub.2--, --C(.dbd.O)--, --O--, --C(R.sup.6)(R.sup.7)--, --N(R.sup.5)-- or --C(.dbd.N(R.sup.5)
7652020 Compounds for the treatment of inflammatory disorders January 26, 2010
This invention relates to compounds of the Formula (I): ##STR00001## or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF-.alpha. or combinations thereof.
7598242 Compounds for the treatment of inflammatory disorders October 6, 2009
This invention relates to compounds of the Formula (I): ##STR00001## or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, TNF-.alpha. or combinations thereof.
7592348 Heterocyclic aspartyl protease inhibitors September 22, 2009
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, --C(.dbd.S)--, --S(O)--, --S(O).sub.2--, --C(.dbd.O)--, --O--, --C(R.sup.6)(R.sup.7)--, --N(R.sup.5)-- or --C(.dbd.N(R.sup.5)
7560451 Aspartyl protease inhibitors July 14, 2009
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, and R.sup.7 are as defined in the specification; and pharmaceutical compositions
7504391 Selective D.sub.1/D.sub.5 receptor antagonists for the treatment of obesity and CNS disorders March 17, 2009
The present invention provides compounds, which, are novel antagonists for D.sub.1/D.sub.5 receptors as well as methods for preparing such compounds. In another embodiment, the invention provides pharmaceutical compositions comprising such D.sub.1/D.sub.5 receptor antagonists as well
7459450 Neuropeptide receptor modulators December 2, 2008
The present invention discloses compounds, which are novel receptor antagonists for NPY Y1 as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such NPY Y1 receptor antagonists as well as methods of usi
7034057 Compounds for the treatment of inflammatory disorders April 25, 2006
This invention relates to compounds of the Formula (I): ##STR00001## or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, TNF-.alpha. or combinations thereof.
6838466 Compounds for the treatment of inflammatory disorders January 4, 2005
This invention relates to compounds of the Formula (I): ##STR1##or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, TNF-.alpha. or combinations thereof.










 
 
  Recently Added Patents
Method and system for automatically identifying wireless signal quality of a region
Rear body panel cover for a motor vehicle
Systems and methods for classifying electronic information using advanced active learning techniques
Curable sublimation marking material and sublimation transfer process using same
Apparatus and method for foreground detection
Method for cutting C--Mn steel with a fiber laser
High-order harmonic device of cavity filter
  Randomly Featured Patents
Cell-free extract and glycoprotein synthesis system
Method of making an MOS transistor having improved transconductance and short channel characteristics
Method for producing channels and cavities in semiconductor housings, and an electronic component having such channels and cavities
Translation system, dictionary updating server, translation method, and program and recording medium for use therein
Flexible aryl alkyl epoxy resins, their amine resin derivatives and their use in electrodeposition coatings
Fixture cleaner
Carton lid
Inhibitory effects of synthetic and natural colorants on carcinogenesis III
Detergent composition comprising cationic ester surfactant and protease enzyme
Self-aligned drain/channel junction in vertical pass transistor DRAM cell design for device scaling